Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Cancer Prev Res (Phila). 2014 Apr 25;7(7):686–697. doi: 10.1158/1940-6207.CAPR-13-0359

Table 5.

Comparison of MD Anderson results to similarly designed, population-based endometrial cancer national and international studies.

MDACC1
N = 408		 Ohio State2
N = 140		 Netherlands3
N = 179
% IHC Loss 28.9 21.4 23.5
% MLH1 Loss 22.0 17.1 17.9
% MLH1 methylated 82.7 Not performed 96.9
% Probable Lynch Syndrome 10.5 6.7–10.14 6 (3–11)
1

MDACC, MD Anderson Cancer Center (4 of the initial 412 patients studied excluded because immunohistochemistry and/or MLH1 methylation did not work)

2

Backes et al. investigation of 140 endometrial carcinomas with immunohistochemistry for expression of DNR mismatch repair proteins (32).

3

Leenen et al. investigation of 179 endometrial carcinomas with immunohistochemistry and MLH1 methylation analysis in all patients diagnosed at less than age 50 (33).

4

Ohio State calculation of % probable Lynch Syndrome is based on an approximate 82.7–96.9% range of MLH1 methylation rate of tumors with immunohistochemical loss of MLH1 found in the MDACC and Netherlands studies.